Form 4: 4D Molecular Therapeutics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc., sold 1,635 shares of common stock on September 16, 2026 for $13.65 per share.

Summary

  • Option exercise/conversion: acquired 1,635 Common Stock at $4.14 ($6,769) on September 16, 2026; holds 10,252 after (Direct).
  • Open-market sale: disposed of 1,635 Common Stock at $13.65 ($22,318) on September 16, 2026; holds 8,617 after (Direct).
  • Option exercise/conversion: disposed of 1,635 Stock Option (Right to Buy) on September 16, 2026; holds 58,066 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $22,318 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Scott Bizily — Officer (Chief Legal Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-16Option exercise/conversionCommon Stock1,635$4$6.8K10,252
2026-09-16Open-market saleCommon Stock1,635$14$22.3K8,617
2026-09-16Option exercise/conversionStock Option (Right to Buy)1,635——58,066

Key Dates

DateDescription
2026-09-16Option exercise/conversion (1,635 shares)
2026-09-16Open-market sale (1,635 shares)
2026-09-16Option exercise/conversion (1,635 shares)

Keywords

insider transaction, Form 4, FDMT, 4D Molecular Therapeutics, Inc., bearish, Scott Bizily

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.